Drug intelligence / Profile preview

DINA-006

Development stage: Preclinical
Lead developer: DiNAQOR
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies

Overview

DINA-006 is an investigational gene therapy developed by DiNAQOR for the treatment of dilated cardiomyopathy, a form of heart muscle disease. It utilizes an adeno-associated virus (AAV) vector to deliver therapeutic genetic material to cardiac tissue. The therapy is currently in preclinical development and aims to address underlying genetic causes of dilated cardiomyopathy, potentially offering a disease-modifying approach for patients with this serious cardiovascular condition[1][4][7].

Beyond the preview

Go deeper on DINA-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DINA-006.

Explore the full profile